NEXCAR19 VS KYMRIAH
IN INDIA
Both CAR-T products are approved in India. Both target CD19. The decision between them depends on your diagnosis, age, financial situation, insurance status, and centre preference. This guide walks through every dimension.
analyticsAt a Glance
- check_circleNexCAR19: ~$30โ40K vs Kymriah India: ~$150โ200K
- check_circleComparable efficacy in B-ALL; Kymriah has more data in DLBCL and follicular lymphoma
- check_circleNexCAR19 shows lower grade 3+ CRS (6% vs ~22% for Kymriah in ELIANA)
- check_circleBoth CDSCO-approved; NexCAR19 available at TMC, Kymriah at Apollo/Manipal/Fortis
Side-by-Side Comparison: NexCAR19 vs Kymriah in India
A direct comparison across all clinically and practically relevant dimensions for a patient deciding between the two approved CAR-T products in India.
| Factor | NexCAR19 (ImmunoACT) | Kymriah (Immuneel/Novartis) |
|---|---|---|
| Cost (therapy) | ~$30,000โ40,000 USD | ~$150,000โ200,000 USD |
| Cost (all-in India) | ~$40,000โ55,000 USD | ~$180,000โ250,000 USD |
| Cost (USA list price) | Not available in USA | $475,000 USD |
| Developer | ImmunoACT (IIT Bombay + TMC) | Novartis / Immuneel India |
| CDSCO Approved | Yes โ October 2023 | Yes |
| B-ALL indication | All ages (paediatric + adult) | Up to age 25 |
| DLBCL indication | Yes (adult r/r after 2+ lines) | Yes (adult r/r after 2+ lines) |
| Follicular lymphoma | Not approved | Yes (r/r grade 1โ3A) |
| B-ALL CR rate | 81% (pivotal trial, n=21) | 81% (ELIANA trial, n=75) |
| DLBCL CR rate | 58% (pivotal trial, n=12) | ~40% CR (JULIET trial) |
| Grade 3+ CRS | 6% | ~22% (ELIANA) |
| Manufacturing time | 3โ4 weeks | 3โ4 weeks |
| Manufacturing site | IIT Bombay, Mumbai | Immuneel facility, India |
| Primary centres | Tata Memorial Centre Mumbai | Apollo, Manipal, Fortis |
| International patient access | Yes โ via CancerFax coordination | Yes โ via CancerFax coordination |
Cost Comparison Across Markets
Both Indian options offer dramatic cost reductions vs the US. NexCAR19 is approximately 3โ4x cheaper than Kymriah in India.
CAR-T Therapy Cost by Product and Market (USD)
- NexCAR19 India$35K
- Kymriah India (Immuneel)$175K
- Kymriah USA$475K
Efficacy and Safety at a Glance
- 81% / 81%B-ALL CR RateNexCAR19 and Kymriah achieve identical 81% CR in B-ALL across their respective pivotal trials.
- 58% vs ~40%DLBCL CR RateNexCAR19 showed 58% CR vs Kymriah JULIET trial's ~40% CR โ but patient populations differ.
- 6% vs ~22%Grade 3+ CRSNexCAR19's 6% severe CRS vs ~22% for Kymriah in ELIANA โ a meaningful safety difference.
- 3โ4 wksManufacturing TimeBoth products have comparable 3โ4 week manufacturing turnaround from leukapheresis.
For International Patients: Practical Considerations
International patients have additional factors to weigh beyond the clinical comparison โ particularly insurance, visa, logistics, and language support at the treating centre.
Check Policy Name Before Choosing
Some international insurance policies name Kymriah explicitly (as an FDA-approved product) and may not yet recognise NexCAR19. Verify with your insurer before committing to a product โ if Kymriah is reimbursable and NexCAR19 is not, the effective cost difference may narrow considerably.
International Patient Facilities
Apollo Hospitals (Kymriah) and Tata Memorial Centre (NexCAR19) both have international patient departments with English-speaking staff. Apollo and Manipal have broader experience with Gulf, African, and Southeast Asian patients and offer dedicated international reception services.
More from the CAR-T India Resource Library
Dig deeper into either product or explore disease-specific and access guides.
- CAR-T Cell Therapy in India โ Complete Guide
- What Is NexCAR19 and Why Is It the World's Most Affordable CAR-T?
- Kymriah in India Through Immuneel: Who Should Choose It Over NexCAR19?
- CAR-T for B-Cell ALL in India: Paediatric and Adult Programmes
- CAR-T for DLBCL in India: Eligibility, Outcomes, and Access
- How to Access CAR-T Cell Therapy in India via CancerFax
Frequently Asked Questions: NexCAR19 vs Kymriah in India
Is NexCAR19 as safe as Kymriah?
Based on published data, NexCAR19 demonstrates a notably lower rate of severe (grade 3+) CRS than Kymriah's ELIANA trial โ 6% vs approximately 22%. This may reflect differences in the CAR construct, patient selection, or bridging therapy protocols. Both products are CDSCO-approved and managed with equivalent ICU and tocilizumab protocols at their respective treatment centres. No safety concern has been identified that would make NexCAR19 inferior to Kymriah.
Can I switch from NexCAR19 to Kymriah if the first product fails?
There is no established clinical pathway for sequential CD19-directed CAR-T after primary failure โ because disease that is refractory to one CD19 CAR-T product has often downregulated CD19 (antigen escape), making a second CD19-targeting product unlikely to work. Patients who fail NexCAR19 should be assessed for CD19 antigen expression and alternative approaches, which may include CD22-directed therapies, BiTEs, or allogeneic CAR-T trials.
Which product should paediatric patients choose?
For paediatric B-ALL, NexCAR19 is typically the first choice in India given the matched 81% CR rate and significantly lower cost. Kymriah is an equally valid option, particularly for families who have insurance coverage for Kymriah specifically or who prefer the larger global evidence base. There is no clinical evidence suggesting one is superior to the other in paediatric B-ALL.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure Which Product Is Right for Your Case?
CancerFax reviews your medical records and advises on NexCAR19 vs Kymriah based on your diagnosis, age, financial situation, and insurance โ then coordinates access to the right centre.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.